Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AB-101 Following Oral Administration in Healthy and Chronic Hepatitis B Subjects
AB-101-001
Phase 1 other active
Quick answer
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AB-101 Following Oral Administration in Healthy and Chronic Hepatitis B Subjects for Chronic hepatitis B virus Infection is a Phase 1 program (other) at Arbutus Biopharma Corp with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Arbutus Biopharma Corp
- Indication
- Chronic hepatitis B virus Infection
- Phase
- Phase 1
- Modality
- other
- Status
- active